The content on this site is intended for healthcare professionals only
CAR T cells are engineered to target plasma cells and have received FDA approval. These therapies demonstrate sustained responses, especially in refractory multiple myeloma. While there is potential for cures in newly diagnosed patients, long-term disease-free rates are low. Upfront CAR T cell implementation may enhance remission, but managing side effects is crucial. The future looks promising, pending more data.
ASCO GU 2026: Updates in bladder cancer
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Key insights from lung cancer research at ASCO 2025
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
SIOG 2024: Updates in haematology
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Understanding the remaining unmet needs in a post ASCT NDMM setting
